Tech Company Financing Transactions
EIP Pharma Funding Round
EIP Pharma closed a $20.5 million Series B financing round on 5/17/2018. Investors included Access Industries and private investors.
Transaction Overview
Company Name
Announced On
5/17/2018
Transaction Type
Venture Equity
Amount
$20,500,000
Round
Series B
Investors
Access Industries (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to further advance development of neflamapimod, an oral small molecule inhibitor of the intra-cellular enzyme p38 MAP kinase alpha (p38 alpha) being studied in Alzheimer's disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
120 St. James Ave. 6th Floor The Yard 6017
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Not Recorded
Overview
EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Sylvie Grégoire
Chief Executive Officer
John Alam
VP - Bus. Development
Kelly Blackburn
VP - Bus. Development
Darryl Patrick
Browse more venture capital transactions:
Prev: 5/17/2018: HiFiBiO Therapeutics venture capital transaction
Next: 5/17/2018: Lulus venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs